[Treatment of neuroendocrine tumours of the gastrointestinal tract].
The prognosis of neuroendocrine tumours of the gastrointestinal tract and pancreas is difficult to estimate due to their heterogeneous nature. Survival without dissemination may reach 90%, while metastases reduce the 5-year survival to less than 50%. Radical surgery offers the only possibility of cure. Palliative therapy includes surgery and intra-arterial embolization of hepatic metastases, chemotherapy, biotherapy with interferon-alpha and radionuclear treatment. Tumour-targeted therapy with tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors or monoclonal antibodies are under investigation in phase-III studies.
Kirurgisk Klinik C, Rigshospitalet, 2100 København Ø, Denmark. city@oncable.dk
Carsten Palnaes
CP
Hansen
Seppo
S
Langer
Susanne
S
Frevert
Jann
J
Mortensen
Andreas
A
Kjaer
Ulrich
U
Knigge
D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary / Q000601:surgery; D018358:Neuroendocrine Tumors / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D017410:Practice Guidelines as Topic; D011379:Prognosis
D000970:Antineoplastic Agents